Otsuka Pharmaceutical Co. Ltd. has entered into a definitive agreement to pay around $430m in cash for the private US antibody technology venture Visterra Inc., in a step the major Japanese pharma firm says will boost its presence in renal and infectious diseases with unmet needs.
The deal, already approved by both companies' boards, is expected to close in the third quarter subject to usual antitrust...








